Edition:
United Kingdom

Aakash B

AstraZeneca's cancer drug disappoints as potential COVID-19 treatment

12 Nov 2020

AstraZeneca's blood cancer treatment, Calquence, failed to improve survival rates and prevent lung failure in patients hospitalised with symptoms of COVID-19, the drugmaker said on Thursday, citing results from mid-stage trials.

Great Portland's retail portfolio valuation plunges on pandemic hit

11 Nov 2020

Property developer Great Portland Estates on Wednesday reported an 18% plunge in the valuation of its retail portfolio as coronavirus restrictions hit the industry, and said office take-up in central London had dropped to record lows.

UPDATE 2-UK property group LandSec restores dividend even as losses soar

10 Nov 2020

* Like-for-like net rental income down 10% (Adds analyst comment, shares)

Property firm Connells approaches Countrywide about possible buyout

09 Nov 2020

Britain's Countrywide Plc has been approached by real estate management firm Connells Ltd about a possible buyout that would value the real estate agent at around 82 million pounds ($108 million).

COVID curbs threaten UK economy, Wetherspoons says, as plunges to loss

16 Oct 2020

LONDON J D Wetherspoon accused the British government of panicking and "shooting from the hip" with new coronavirus restrictions it said could damage the entire economy, after the pubs group reported its first annual loss since 1984.

Weir Group to sell oil & gas division to Caterpillar, shares surge

05 Oct 2020

Weir Group Plc said on Monday it had agreed to sell its oil and gas division to U.S. heavy equipment maker Caterpillar Inc for $405 million in cash, as the engineering company focuses on its mining business.

G4S rejects $3.81 billion hostile bid from private equity-backed GardaWorld

30 Sep 2020

Security group G4S on Wednesday rejected a cash offer by smaller Canadian rival GardaWorld that valued the British company at 2.97 billion pounds ($3.81 billion), weeks after it turned down a similar proposal.

EU agency recommends AstraZeneca-Merck drug Lynparza for two cancers

21 Sep 2020

The European Medicines Agency (EMA) has recommended approval for Lynparza in patients with a form of prostate cancer and as a first-line maintenance treatment for a form of advanced ovarian cancer, the British drugmaker AstraZeneca said on Monday.

World News